In a recent study published in JAMA Network Open , researchers investigated the reliability of eye-tracking biological markers in distinguishing autistic children from non-autistic ones during clinical evaluations in community-based settings. They also determined whether combining biological markers with primary care physician (PCP) diagnoses and diagnosis certainty improved diagnostic outcomes. Racial and ethnic minority children, as well as underprivileged communities, increase autism diagnosis gaps.
Long wait periods for assessments are due to the large number of children who require evaluations, which exceeds the number of specialists. Diagnostic delays impede early, evidence-based therapies, lowering long-term care expenses. To address the problem, new community-based care delivery models are under development that combine clinical and biobehavioral methods to increase early diagnostic accuracy and timeliness.
Eye-tracking biological markers, which are non-invasive, low-cost, and practicable, show promise for detecting early autism diagnostic biomarkers. In the present prospective diagnostic study, researchers investigated the reliability of eye-tracker biological markers used in primary care clinical evaluations to identify autistic children in community settings. They determined whether combining these biomarkers with PCP diagnoses would improve diagnostic accuracy.
Between 7 June 2019 and 23 September 2022, the Early Autism Evaluation (EAE) PCPs recommended a sequenti.
